This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MarketVIEW: Dengue Vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

MarketVIEW: Dengue vaccines

Dengue fever (DF) is a mosquito-borne disease (Aedes) which can affect two fifths of the world's population. DF infection has a wide spectrum of symptoms that range from a mild febrile illness to severe outcomes, even death as observed in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Importantly, of the 22,000 estimated deaths per year, the large majority are in children (< 15yrs) where no specific treatment is available.

This MarketVIEW product forecasts the potential commercial value of dengue fever vaccine(s) across endemic and travelers markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector. LO and HI forecast scenarios which include expected demand from country selected catch-up campaigns are also detailed along with discussion of development considerations of the ideal dengue vaccine(s) in light of current pipeline candidates.


Contents – Summary presentation (MS PowerPoint based)Author's noteExecutive SummaryCommercial model – key outputsSummary for total number of CDI cases (theoretical and treated) in Emerging + ROW region2020 Snapshot CDI cases (theoretical)Deploying C.diff vaccines: primary prevention (PX)C.diff vaccines: three potential markets modelledPX indication (community) – total predicted demand (doses 000s)PX indication (community) – total available market ($ USD 000s)PX indication (hospital admission) – total available market ($ USD 000s)TX indication (hospital) – total predicted demand (doses 000s)TX indication (hospital) – total available market ($ USD 000s)C.diff vaccines: total commercial summary (peak)C.diff vaccines – key model assumptionsC.diff vaccines – countries included in modelCommunity prophylaxis – major model assumptionsPrevention of CDI recurrences (TX) – major model assumptionsHospital prophylaxis – major model assumptionsPrimary research – summary of findingsC.diff (CDI) situation analysisPrimary research respondentsExpert viewpoints: nosocomial infections in generalExpert viewpoints: major pathogensExpert viewpoints: reporting surveillanceBrazil: National Health Surveillance Agency (ANVISA) Mexico: National Health Surveillance Agency (SALUD)Expert viewpoints: nosocomial infections – incidence estimatesExpert viewpoints: awareness of Clostridium difficileExpert viewpoints: is CDI a growing problem?Expert viewpoints: test for Clostridium difficileExpert viewpoints: C.diff molecular epidemiologyC.diff as a % of nosocomial diarrhea – Emerging markets/ROW regionExpert viewpoints: treating CDICountry environment factors contributing to CDIExpert viewpoints: (use) misuse of antibioticsExpert viewpoints: role of hospitals (LOS)Expert viewpoints: elderly care/the role of nursing homesOther notable patient factorsExpert Reaction to C.diff R&D pipeline and vaccinesCDI pipeline: by estimated filing dateExpert viewpoints: CDI R&D pipeline (all)Expert viewpoints: C.diff vaccines – general commentsExpert viewpoints: deploying C.diff vaccinesExpert viewpoints: funding C.diff vaccinesBack-up and source materialCDI – Western marketsDefinition of at-risk population (community vaccination)About VacZine AnalyticsDisclaimerPAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based)Title sheetCHARTS (PX) comm.CHARTS (PX) hospCHARTS (TX)CHARTS (Epi)Val/Vol summary (PX comm)Val/Vol summary (PX hosp)Val/Vol summary (TX)Vaccine pricing forecastEpi summary – CDIProphylaxis (hosp admission)All admissions (>65 yrs)Emer admissions (>65yrs)Elect admissions (>65yrs)PX > 65yrs (comm) and TX (RD – first line)BrazilRussiaIndiaChinaArgentinaChileColumbiaVenezuelaTurkeySaudi ArabiaPolandCzech RepublicSlovakiaHungarySouth AfricaMalaysiaSingaporeIndonesiaPhilippinesThailandSouth KoreaSource materialNosocomial diarrhea (CDIFF)Hospital admissions forecastHospital beds – admissionsChina – hospital statisticsBrazil – hospital statisticsHospital beds (historical)Hospital discharges (historical)Population database (all ages)Population database (65 – 90 yrs)Hospital admission breakdown by typeBack-pageWORKSHEETS: ~65

To order this report:: MarketVIEW: Dengue vaccines

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 -2.67%
FB $104.07 -5.81%
GOOG $683.57 -3.45%
TSLA $162.60 -7.26%
YHOO $27.97 -4.05%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs